The authors would like to acknowledge the valuable contributions of the following persons whose participation made this study possible: the subjects and families; Enio Martinez; Universidad de Valle de Guatemala; Noemi Mazamigo, Regional Health Nurse, Guazacapan, Guatemala; Cesar Barrera, Regional Health Nurse, Cuilapa, Guatemala; and Raquel Vaquez, Regional Health Nurse, Chiquimulilla, Guatemala.
Ward NA, Milstien JB, Hull HF, Hull BP, Kim-Farley RJ, 1993. The WHO-EPI initiative for the global eradication of poliomyelitis. Biologicals 21: 327–333.
Barzegar M, Dastgiri S, Karegarmaher MH, Varshochiani A, 2007. Epidemiology of childhood Guillan-Barre syndrome in the north west of Iran. BMC Neurol 7: 22.
Hart DE, Rojas LA, Rosario JA, Recalde H, Roman GC, 1994. Childhood Guillain-Barre syndrome in Paraguay, 1990 to 1991. Ann Neurol 36: 859–863.
Hussain IH, Ali S, Sinniah M, Kurup D, Khoo TB, Thomas TG, Apandi M & Taha AM 2004. Five-year surveillance of acute flaccid paralysis in Malaysia. J Paediatr Child Health 40: 127–130.
London L, Bourne D, Sayed R, Eastman R, 2004. Guillain-Barre syndrome in a rural farming district in South Africa: a possible relationship to environmental organophosphate exposure. Arch Environ Health 59: 575–580.
Rocha MS, Brucki SM, Carvalho AA, Lima UW, 2004. Epidemiologic features of Guillain-Barre syndrome in Sao Paulo, Brazil. Arq Neuropsiquiatr 62: 33–37.
Shafqat S, Khealani BA, Awan F, Abedin SE, 2006. Guillain-Barre syndrome in Pakistan: similarity of demyelinating and axonal variants. Eur J Neurol 13: 662–665.
Visudtibhan A, Visudhiphan P, Chiemchanya S, Wiengperm M, 1998. Guillain-Barre syndrome in Thai children: retrospective analysis of the clinical and outcome prior to intravenous immune globulin era. J Med Assoc Thai 81: 750–756.
Arvelo W, ed, 2006. Community household survey to describe healthcare utilization practices and risk factors for diarrheal diseases in the Department of Santa Rosa, Guatemala–2006 (Abstract #988). Proceedings of the 45th Annual Meeting of the Infectious Diseases Society of America; San Diego, CA, October 2007.
Kuwabara S, Yuki N, Koga M, Hattori T, Matsuura D, Miyake M, Noda M, 1998. IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barre syndrome. Ann Neurol 44: 202–208.
Berger AR, Logigian EL, Shahani BT, 1988. Reversible proximal conduction block underlies rapid recovery in Guillain-Barre syndrome. Muscle Nerve 11: 1039–1042.